Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
Identifying high-impact solutions to address racial and ethnic health disparities in lupus: A consensus-based approach
This study used a consensus-based approach to identify high-impact solutions for reducing racial and ethnic health disparities in lupus. Through a literature...